Latest News for HKMPF
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026. Executive chair Said Darwazah will become full-time chief executive for the next two years, with current chief financial officer Khalid Nabilsi becoming deputy chief executive with responsibility for North America and Europe.
Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Risk and Volatility ProPhase Labs has a beta
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HKMPF.
Senate Trading
No Senate trades found for HKMPF.
U.S. House Trading
No House trades found for HKMPF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.